4.7 Article

Clinical impact of a highly prevalent Pseudomonas aeruginosa clone in Dutch cystic fibrosis patients

期刊

CLINICAL MICROBIOLOGY AND INFECTION
卷 17, 期 3, 页码 382-385

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1469-0691.2010.03295.x

关键词

Clone; cross-infection; cystic fibrosis; MLST; Pseudomonas aeruginosa

资金

  1. Ipsat therapies
  2. 3M
  3. Cepheid
  4. Novartis
  5. Bayer
  6. Pfizer
  7. Netherlands Organization for Scientific Research (VICI NWO) [918.76.611]

向作者/读者索取更多资源

Studies suggest that infection with highly prevalent Pseudomonas aeruginosa clones in cystic fibrosis (CF) is associated with an unfavourable clinical outcome. We studied the clinical characteristics of patients infected with a recently described, highly prevalent P. aeruginosa clone (ST406) in two CF centres in The Netherlands. Multilocus sequence typing data were available for 219 patients, of whom 40 (18.3%) were infected with ST406 and 179 with other sequence types. ST406 infection was independently associated with age, having a sibling with ST406 infection and use of inhaled antibiotics, but not with unfavourable clinical outcome, suggesting that high transmissibility is not necessarily associated with high virulence.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据